Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase EARLY_PHASE1 1Phase 3 1

Status

Active not recruiting 17Recruiting 16Unknown 4Terminated 4Not yet recruiting 3Completed 3Withdrawn 1

Sponsor Class

INDUSTRY 7OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 1

Conditions

Multiple Myeloma 3Hematologic Neoplasms 1

Interventions

Cyclophosphamide 241Radiotherapy 217Gemcitabine 187Cisplatin 185Carboplatin 182Docetaxel 166Bevacizumab 166Paclitaxel 144Capecitabine 142Rituximab 141pembrolizumab 139Nivolumab 126Oxaliplatin 124Dexamethasone 122Fluorouracil 113fludarabine 104Radiosurgery 101Doxorubicin 99fludarabine phosphate 97Irinotecan 96Etoposide 95Lenalidomide 93Cytarabine 92Magnetic Resonance Spectroscopy 90Radiation 89Filgrastim 89Leucovorin 88Bortezomib 86Cetuximab 80Pemetrexed 79

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × OTHER × isatuximab × Clear all
NCT05675319 2026-01-05

AlloRelapseMM

Universitätsklinikum Hamburg-Eppendorf

Phase 3 Terminated
28 enrolled
Plasma cell

Multiple Myeloma

NCT05284032 2024-07-31

A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)

University of Virginia

Phase EARLY_PHASE1 Terminated
3 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT04083898 2024-03-19

Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma

Washington University School of Medicine

Phase 1 Terminated
15 enrolled
Plasma cell

Multiple Myeloma

NCT04912427 2024-02-09

Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease

Washington University School of Medicine

Phase 1 Terminated
1 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡